Transesophageal echocardiographic guidance of transcatheter closure of the aortic valve in a patient with left ventricular assist device-related severe aortic regurgitation

• Published in: Echo research and practice Vol. 4; no. 2; pp. I7 - I9
• Main Authors: Muskula, Preetham R, Khumri, Taiyeb M, Main, Michael L
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.06.2017; Springer Nature B.V; BMC
• Subjects: Doppler effect; Images and Videos; Surgeons; Ultrasonic imaging
• ISSN: 2055-0464; 2055-0464
• DOI: 10.1530/ERP-17-0003

SummaryA 68-year-old man with a severe ischemic cardiomyopathy underwent left ventricular assist device (LVAD) implantation (Heart Mate II device) for destination therapy. He presented 49 months after LVAD implantation with worsening heart failure symptoms and new severe aortic regurgitation. Given high risk for both surgical and transcatheter aortic valve replacement, he was admitted for transcatheter closure of the aortic valve under transesophageal echocardiographic (TEE) guidance. TEE imaging revealed severe aortic regurgitation (Fig. 1A and B and Videos 1 and 2). Under TEE and fluoroscopic guidance, a 25 mm Amplatzer cribriform atrial septal defect closure device was advanced across the aortic valve (Fig. 1C and D and Videos 3 and 4). Immediately after device deployment, TEE revealed a well-seated device with complete aortic valve closure and trivial aortic regurgitation (Fig. 2A, B, C and D and Videos 5, 6, 7 and 8). Subsequent transthoracic echocardiograms obtained from 74 to 172 days after the procedure revealed no residual aortic regurgitation. The patient awoke with diffuse urticaria 244 days after the procedure and died en route to the emergency department, presumably secondary to a systemic allergic reaction. De novo aortic regurgitation is increasingly recognized in patients with LVADs (1). TEEguided transcatheter aortic valve closure is an option in these high-risk patients (2).